BOSTON SCIENTIFIC CORP (BSX.DE) Stock Fundamental Analysis
FRA:BSX - Deutsche Boerse Ag - US1011371077 - Common Stock - Currency: EUR
Taking everything into account, BSX scores 5 out of 10 in our fundamental rating. BSX was compared to 57 industry peers in the Health Care Equipment & Supplies industry. BSX has an excellent profitability rating, but there are some minor concerns on its financial health. BSX is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
BSX had positive earnings in the past year.
BSX had a positive operating cash flow in the past year.
Of the past 5 years BSX 4 years were profitable.
Each year in the past 5 years BSX had a positive operating cash flow.
1.2 Ratios
BSX's Return On Assets of 5.06% is fine compared to the rest of the industry. BSX outperforms 71.93% of its industry peers.
BSX's Return On Equity of 9.15% is fine compared to the rest of the industry. BSX outperforms 68.42% of its industry peers.
BSX's Return On Invested Capital of 7.57% is fine compared to the rest of the industry. BSX outperforms 71.93% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BSX is in line with the industry average of 8.12%.
The 3 year average ROIC (6.54%) for BSX is below the current ROIC(7.57%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.06% | ||
| ROE | 9.15% | ||
| ROIC | 7.57% |
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.54%
ROIC(5y)5.68%
1.3 Margins
BSX has a Profit Margin of 11.58%. This is in the better half of the industry: BSX outperforms 77.19% of its industry peers.
BSX's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 18.78%, BSX belongs to the top of the industry, outperforming 82.46% of the companies in the same industry.
In the last couple of years the Operating Margin of BSX has remained more or less at the same level.
BSX has a better Gross Margin (68.65%) than 77.19% of its industry peers.
BSX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.78% | ||
| PM (TTM) | 11.58% | ||
| GM | 68.65% |
OM growth 3Y0.33%
OM growth 5Y1.13%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.3%
GM growth 5Y-0.65%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BSX is destroying value.
BSX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BSX has been increased compared to 5 years ago.
BSX has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 6.04 indicates that BSX is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.04, BSX belongs to the top of the industry, outperforming 91.23% of the companies in the same industry.
BSX has a debt to FCF ratio of 3.75. This is a good value and a sign of high solvency as BSX would need 3.75 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.75, BSX is in the better half of the industry, outperforming 75.44% of the companies in the same industry.
A Debt/Equity ratio of 0.47 indicates that BSX is not too dependend on debt financing.
BSX has a Debt to Equity ratio (0.47) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.47 | ||
| Debt/FCF | 3.75 | ||
| Altman-Z | 6.04 |
ROIC/WACC0.88
WACC8.59%
2.3 Liquidity
A Current Ratio of 1.45 indicates that BSX should not have too much problems paying its short term obligations.
With a Current ratio value of 1.45, BSX perfoms like the industry average, outperforming 40.35% of the companies in the same industry.
BSX has a Quick Ratio of 1.45. This is a bad value and indicates that BSX is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.88, BSX is not doing good in the industry: 64.91% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.45 | ||
| Quick Ratio | 0.88 |
3. Growth
3.1 Past
BSX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.17%, which is quite impressive.
BSX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 9.56% yearly.
Looking at the last year, BSX shows a quite strong growth in Revenue. The Revenue has grown by 19.35% in the last year.
The Revenue has been growing by 9.30% on average over the past years. This is quite good.
EPS 1Y (TTM)26.17%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%33.93%
Revenue 1Y (TTM)19.35%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%20.93%
3.2 Future
BSX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.43% yearly.
The Revenue is expected to grow by 10.66% on average over the next years. This is quite good.
EPS Next Y17.44%
EPS Next 2Y15.26%
EPS Next 3Y14.33%
EPS Next 5Y12.43%
Revenue Next Year17.34%
Revenue Next 2Y13.99%
Revenue Next 3Y12.68%
Revenue Next 5Y10.66%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 38.54 indicates a quite expensive valuation of BSX.
BSX's Price/Earnings ratio is in line with the industry average.
Compared to an average S&P500 Price/Earnings ratio of 27.50, BSX is valued a bit more expensive.
BSX is valuated quite expensively with a Price/Forward Earnings ratio of 31.18.
BSX's Price/Forward Earnings is on the same level as the industry average.
The average S&P500 Price/Forward Earnings ratio is at 36.44. BSX is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 38.54 | ||
| Fwd PE | 31.18 |
4.2 Price Multiples
63.16% of the companies in the same industry are cheaper than BSX, based on the Enterprise Value to EBITDA ratio.
The rest of the industry has a similar Price/Free Cash Flow ratio as BSX.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 51.04 | ||
| EV/EBITDA | 35.85 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
BSX has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as BSX's earnings are expected to grow with 14.33% in the coming years.
PEG (NY)2.21
PEG (5Y)4.03
EPS Next 2Y15.26%
EPS Next 3Y14.33%
5. Dividend
5.1 Amount
BSX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:BSX (7/17/2025, 7:00:00 PM)
89.8
+1.6 (+1.81%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners93.03%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap132.85B
Analysts84.62
Price Target104.84 (16.75%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.08%
Min EPS beat(2)5.6%
Max EPS beat(2)10.56%
EPS beat(4)4
Avg EPS beat(4)7.06%
Min EPS beat(4)5.6%
Max EPS beat(4)10.56%
EPS beat(8)8
Avg EPS beat(8)6.71%
EPS beat(12)11
Avg EPS beat(12)5.15%
EPS beat(16)15
Avg EPS beat(16)4.51%
Revenue beat(2)2
Avg Revenue beat(2)1.51%
Min Revenue beat(2)0.97%
Max Revenue beat(2)2.04%
Revenue beat(4)4
Avg Revenue beat(4)1.92%
Min Revenue beat(4)0.97%
Max Revenue beat(4)3.16%
Revenue beat(8)8
Avg Revenue beat(8)2.02%
Revenue beat(12)10
Avg Revenue beat(12)1.79%
Revenue beat(16)12
Avg Revenue beat(16)1.49%
PT rev (1m)0.06%
PT rev (3m)-4.54%
EPS NQ rev (1m)0.07%
EPS NQ rev (3m)2.46%
EPS NY rev (1m)0.15%
EPS NY rev (3m)2.02%
Revenue NQ rev (1m)0.02%
Revenue NQ rev (3m)2.4%
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)1.62%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 38.54 | ||
| Fwd PE | 31.18 | ||
| P/S | 8.76 | ||
| P/FCF | 51.04 | ||
| P/OCF | 40.35 | ||
| P/B | 6.93 | ||
| P/tB | N/A | ||
| EV/EBITDA | 35.85 |
EPS(TTM)2.33
EY2.59%
EPS(NY)2.88
Fwd EY3.21%
FCF(TTM)1.76
FCFY1.96%
OCF(TTM)2.23
OCFY2.48%
SpS10.25
BVpS12.97
TBVpS-0.99
PEG (NY)2.21
PEG (5Y)4.03
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.06% | ||
| ROE | 9.15% | ||
| ROCE | 9.4% | ||
| ROIC | 7.57% | ||
| ROICexc | 7.73% | ||
| ROICexgc | 25.4% | ||
| OM | 18.78% | ||
| PM (TTM) | 11.58% | ||
| GM | 68.65% | ||
| FCFM | 17.17% |
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.54%
ROIC(5y)5.68%
ROICexc(3y)6.7%
ROICexc(5y)5.9%
ROICexgc(3y)22.68%
ROICexgc(5y)19.43%
ROCE(3y)8.12%
ROCE(5y)7.05%
ROICexcg growth 3Y8.56%
ROICexcg growth 5Y6.81%
ROICexc growth 3Y4.36%
ROICexc growth 5Y5.23%
OM growth 3Y0.33%
OM growth 5Y1.13%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.3%
GM growth 5Y-0.65%
F-Score5
Asset Turnover0.44
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.47 | ||
| Debt/FCF | 3.75 | ||
| Debt/EBITDA | 2.3 | ||
| Cap/Depr | 61.86% | ||
| Cap/Sales | 4.55% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 83.12% | ||
| Profit Quality | 148.25% | ||
| Current Ratio | 1.45 | ||
| Quick Ratio | 0.88 | ||
| Altman-Z | 6.04 |
F-Score5
WACC8.59%
ROIC/WACC0.88
Cap/Depr(3y)57.82%
Cap/Depr(5y)54.13%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.85%
Profit Quality(3y)134.31%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.17%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%33.93%
EPS Next Y17.44%
EPS Next 2Y15.26%
EPS Next 3Y14.33%
EPS Next 5Y12.43%
Revenue 1Y (TTM)19.35%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%20.93%
Revenue Next Year17.34%
Revenue Next 2Y13.99%
Revenue Next 3Y12.68%
Revenue Next 5Y10.66%
EBIT growth 1Y30.17%
EBIT growth 3Y12.47%
EBIT growth 5Y10.54%
EBIT Next Year32.67%
EBIT Next 3Y19.08%
EBIT Next 5Y13.71%
FCF growth 1Y151.8%
FCF growth 3Y26.15%
FCF growth 5Y16.61%
OCF growth 1Y114.76%
OCF growth 3Y22.44%
OCF growth 5Y13.34%